1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Medicine

Cancer Oncology

Immunology

Molecular Biology

Antigen

Show all topics

DOI

10.1136/jitc-2024-sitc2024.1486

License

CC-BY-NC

Other Formats

PDF